Abstract
The drug discovery process is complex, time consuming and expensive, and includes preclinical and clinical phases. The pharmaceutical industry is moving from a symptomatic relief focus towards a more pathology-based approach where a better understanding of the pathophysiology should help deliver drugs whose targets are involved in the causative processes underlying the disease. Computational biology and bioinformatics have the potential not only to speed up the drug discovery process, thus reducing the costs, but also to change the way drugs are designed. In this review we focus on the different computational and bioinformatics approaches that have been proposed and applied to the different steps involved in the drug development process. The development of network-reconstruction methods is now making it possible to infer a detailed map of the regulatory circuit among genes, proteins and metabolites. It is likely that the development of these technologies will radically change, in the next decades, the drug discovery process, as we know it today.
Keywords: lead identification, Supervised-learning methods, Leukemia, titration-invariant similarity score (TISS), bioinformatics, reverse engineering
Current Bioinformatics
Title: Computational Biology and Drug Discovery: From Single-Target to Network Drugs
Volume: 1 Issue: 1
Author(s): Alberto Ambesi-Impiombato and Diego d Bernardo
Affiliation:
Keywords: lead identification, Supervised-learning methods, Leukemia, titration-invariant similarity score (TISS), bioinformatics, reverse engineering
Abstract: The drug discovery process is complex, time consuming and expensive, and includes preclinical and clinical phases. The pharmaceutical industry is moving from a symptomatic relief focus towards a more pathology-based approach where a better understanding of the pathophysiology should help deliver drugs whose targets are involved in the causative processes underlying the disease. Computational biology and bioinformatics have the potential not only to speed up the drug discovery process, thus reducing the costs, but also to change the way drugs are designed. In this review we focus on the different computational and bioinformatics approaches that have been proposed and applied to the different steps involved in the drug development process. The development of network-reconstruction methods is now making it possible to infer a detailed map of the regulatory circuit among genes, proteins and metabolites. It is likely that the development of these technologies will radically change, in the next decades, the drug discovery process, as we know it today.
Export Options
About this article
Cite this article as:
Ambesi-Impiombato Alberto and Bernardo d Diego, Computational Biology and Drug Discovery: From Single-Target to Network Drugs, Current Bioinformatics 2006; 1 (1) . https://dx.doi.org/10.2174/157489306775330598
DOI https://dx.doi.org/10.2174/157489306775330598 |
Print ISSN 1574-8936 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-392X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications
Current Cancer Drug Targets Niacin: From Mechanisms of Action to Therapeutic Uses
Mini-Reviews in Medicinal Chemistry Indoxyl Sulfate: A Candidate Target for the Prevention and Treatment of Cardiovascular Disease in Chronic Kidney Disease
Current Drug Targets MicroRNAs in Noise-Induced Hearing Loss and their Regulation by Oxidative Stress and Inflammation
Current Drug Targets An Update on the Recent Advances in Cubosome: A Novel Drug Delivery System
Current Drug Metabolism Dual Modulators of Selected Plant Secondary Metabolites Targeting COVID-19 Main Protease and Interleukin-2: An <i>In-Silico</i> Approach based Novel Hypothesis
Coronaviruses Herb-Drug Interactions and Mechanistic and Clinical Considerations
Current Drug Metabolism Large A-V Fistula: Pathophysiological Consequences and Therapeutic Perspectives
Current Vascular Pharmacology Editorial [Hot Topic: Bone and Immune System Cross-Talk (Guest Editors: Nadia Rucci and Hiroshi Takayanagi)]
Inflammation & Allergy - Drug Targets (Discontinued) Comparative Studies on Phospholipase A2 as a Marker for Gut Microbiota- liver-brain Axis in a rodent Model of Autism
Current Proteomics Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?
Current Drug Targets Alzheimers Disease, Ceramide, Visfatin and NAD
CNS & Neurological Disorders - Drug Targets Current Advances and Future Challenges in Adenoviral Vector Biology and Targeting
Current Gene Therapy <i>In Vivo/Ex Vivo</i> EPR Investigation of the Brain Redox Status and Blood-Brain Barrier Integrity in the 5xFAD Mouse Model of Alzheimer's Disease
Current Alzheimer Research Editorial: Neurobiological Consequences of Oxidative Stress.
Current Neuropharmacology Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19)
Current Pharmaceutical Design Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo
Mini-Reviews in Medicinal Chemistry Role of Cytokines and Matrix Metallo-Proteinases in Patients with Temporo- Mandibular Joint Internal Derangements and/or Osteoarthritis
Recent Patents on Biomarkers Inhaled KMUP-1 Prevents Allergic Pulmonary Vascular Inflammation and Remodeling via NO and Suppressed MMP-9 and ICAM-1/VCAM-1
Inflammation & Allergy - Drug Targets (Discontinued) IL-24: Physiological and Supraphysiological Effects on Normal and Malignant Cells
Current Medicinal Chemistry